Search Results - "BENNETT, Mark K"

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer by Gross, Matt I, Demo, Susan D, Dennison, Jennifer B, Chen, Lijing, Chernov-Rogan, Tania, Goyal, Bindu, Janes, Julie R, Laidig, Guy J, Lewis, Evan R, Li, Jim, Mackinnon, Andrew L, Parlati, Francesco, Rodriguez, Mirna L M, Shwonek, Peter J, Sjogren, Eric B, Stanton, Timothy F, Wang, Taotao, Yang, Jinfu, Zhao, Frances, Bennett, Mark K

“…Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to…”
Get full text

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events by ARASTU-KAPUR, Shirin, ANDERL, Janet L, KIRK, Christopher J, KRAUS, Marianne, PARLATI, Francesco, SHENK, Kevin D, LEE, Susan J, MUCHAMUEL, Tony, BENNETT, Mark K, DRIESSEN, Christoph, BALL, Andrew J

“…Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a…”
Get full text

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment by Steggerda, Susanne M, Bennett, Mark K, Chen, Jason, Emberley, Ethan, Huang, Tony, Janes, Julie R, Li, Weiqun, MacKinnon, Andrew L, Makkouk, Amani, Marguier, Gisele, Murray, Peter J, Neou, Silinda, Pan, Alison, Parlati, Francesco, Rodriguez, Mirna L M, Van de Velde, Lee-Ann, Wang, Tracy, Works, Melissa, Zhang, Jing, Zhang, Winter, Gross, Matthew I

“…Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining…”
Get full text

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome by Parlati, Francesco, Lee, Susan J., Aujay, Monette, Suzuki, Erika, Levitsky, Konstantin, Lorens, James B., Micklem, David R., Ruurs, Paulina, Sylvain, Catherine, Lu, Yan, Shenk, Kevin D., Bennett, Mark K.

“…Carfilzomib is a proteasome inhibitor in clinical development that primarily targets the chymotrypsin-like (CT-L) subunits in both the constitutive proteasome…”
Get full text

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma by Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fijs W.B., Chanan-Khan, Asher A., Orlowski, Robert Z.

“…The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for…”
Get full text

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis by Basler, Michael, Aujay, Monette A, Groettrup, Marcus, Kalim, Khalid W, Shields, Jamie, Jiang, Jing, Kirk, Christopher J, Muchamuel, Tony, Suzuki, Erika, Bennett, Mark K, Ring, Eileen R, Demo, Susan D, Shwonek, Peter, Lauer, Christoph, Sylvain, Catherine, Parlati, Francesco

“…Christopher Kirk and his colleagues have developed the first specific inhibitor of the immunoproteasome. They find that the immunoproteasome has a major role…”
Get full text

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome by DEMO, Susan D, KIRK, Christopher J, SHENK, Kevin D, SMYTH, Mark S, SUN, Congcong M, VALLONE, Marcy K, WOO, Tina M, MOLINEAUX, Christopher J, BENNETT, Mark K, AUJAY, Monette A, BUCHHOLZ, Tonia J, DAJEE, Maya, HO, Mark N, JING JIANG, LAIDIG, Guy J, LEWIS, Evan R, PARLATI, Francesco

“…Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma…”
Get full text

Molecular mechanisms of bortezomib resistant adenocarcinoma cells by Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P Leif, Bennett, Mark K, Kirk, Christopher J

“…Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM). Despite its demonstrated clinical…”
Get full text

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047) by Zhou, Han-Jie, Aujay, Monette A, Bennett, Mark K, Dajee, Maya, Demo, Susan D, Fang, Ying, Ho, Mark N, Jiang, Jing, Kirk, Christopher J, Laidig, Guy J, Lewis, Evan R, Lu, Yan, Muchamuel, Tony, Parlati, Francesco, Ring, Eileen, Shenk, Kevin D, Shields, Jamie, Shwonek, Peter J, Stanton, Timothy, Sun, Congcong M, Sylvain, Catherine, Woo, Tina M, Yang, Jinfu

“…Proteasome inhibition has been validated as a therapeutic modality in the treatment of multiple myeloma and Non-Hodgkin’s lymphoma. Carfilzomib, an epoxyketone…”
Get full text

Syntaxin: A Synaptic Protein Implicated in Docking of Synaptic Vesicles at Presynaptic Active Zones by Bennett, Mark K., Calakos, Nicole, Scheller, Richard H.

“…Synaptic vesicles store neurotransmitters that are released during calcium-regulated exocytosis. The specificity of neurotransmitter release requires the…”
Get full text

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors by Harding, James J, Telli, Melinda, Munster, Pamela, Voss, Martin H, Infante, Jeffrey R, DeMichele, Angela, Dunphy, Mark, Le, Mai H, Molineaux, Chris, Orford, Keith, Parlati, Frank, Whiting, Sam H, Bennett, Mark K, Tannir, Nizar M, Meric-Bernstam, Funda

“…Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the…”
Get full text

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial by Meric-Bernstam, Funda, Tannir, Nizar M, Iliopoulos, Othon, Lee, Richard J, Telli, Melinda L, Fan, Alice C, DeMichele, Angela, Haas, Naomi B, Patel, Manish R, Harding, James J, Voss, Martin H, Owonikoko, Taofeek K, Carthon, Bradley, Srinivasan, Ramaprasad, Bendell, Johanna C, Jenkins, Yonchu, Whiting, Sam H, Orford, Keith, Bennett, Mark K, Bauer, Todd M

“…Dual inhibition of glucose and glutamine metabolism results in synergistic anticancer effects in solid tumor models. Telaglenastat, an investigational,…”
Get full text

The tissue effect of argon plasma coagulation on esophageal and gastric mucosa by Watson, Jonathan P., Bennett, Mark K., Griffin, S.Michael, Matthewson, Kenneth

“…Background: Argon plasma coagulation is a diathermy-based non-contact therapeutic endoscopic modality that may have a lower risk of perforation than other…”
Get full text

Protein-Protein Interactions Contributing to the Specificity of Intracellular Vesicular Trafficking by Calakos, Nicole, Bennett, Mark K., Peterson, Karen E., Scheller, Richard H.

“…Intracellular vesicles destined to fuse with the plasma membrane and secrete their contents must have a mechanism for specifically interacting with the…”
Get full text

Retrovirally Delivered Random Cyclic Peptide Libraries Yield Inhibitors of Interleukin-4 Signaling in Human B Cells by Kinsella, Todd M., Ohashi, Cara T., Harder, Amy Grace, Yam, George C., Li, Weiqun, Peelle, Beau, Pali, Erlina S., Bennett, Mark K., Molineaux, Susan M., Anderson, D.A., Masuda, Esteban S., Payan, Donald G.

“…Inteins are polypeptide sequences found in a small set of primarily bacterial proteins that promote the splicing of flanking pre-protein sequences to generate…”
Get full text

Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms by Kirk, Kevin L, Naren, Anjaparavanda P, Nelson, Deborah J, Xie, Weiwen, Jovov, Biljana, Pevsner, Jonathan, Bennett, Mark K, Benos, Dale J, Quick, Michael W

“…The cystic fibrosis gene encodes a cyclic AMP-gated chloride channel (CFTR) that mediates electrolyte transport across the luminal surfaces of a variety of…”
Get full text

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats by JINFU YANG, ZHENGPING WANG, YING FANG, JING JIANG, FRANCES ZHAO, HANSEN WONG, BENNETT, Mark K, MOLINEAUX, Christopher J, KIRK, Christopher J

“…Carfilzomib…”
Get full text

The synaptic SNARE complex is a parallel four-stranded helical bundle by Bennett, Mark K, Poirier, Michelle A, Xiao, Wenzhong, Macosko, Jed C, Chan, Charles, Shin, Yeon-Kyun

“…The heterotrimeric synaptic soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, consisting of the synaptic…”
Get full text

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay by Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.

“…Summary While proteasome inhibition is a validated therapeutic approach for multiple myeloma (MM), inhibition of individual constitutive proteasome (c20S) and…”
Get full text

Effect of Mutations in Vesicle-Associated Membrane Protein (VAMP) on the Assembly of Multimeric Protein Complexes by Hao, Joe C, Salem, Natalie, Peng, Xiao-Rong, Kelly, Regis B, Bennett, Mark K

“…The assembly of multimeric protein complexes that include vesicle-associated membrane protein 2 (VAMP-2) and the plasma membrane proteins syntaxin 1A and…”
Get full text